Tenet (THC) Up 4% Since Last Earnings Report: Can It Continue?

Tenet Healthcare reported strong Q3 2025 results with adjusted EPS of $3.70 (+26.3% YoY; +11.1% vs. Zacks consensus) and net operating revenues of $5.3 billion (+3.2% YoY; +1% vs. consensus). Adjusted net income was $328 million (+16.3% YoY) and adjusted EBITDA rose 12.4% to $1.1 billion (margin 20.8%, +170 bps), driven by higher same-facility revenues, favorable payer mix and facility buyouts in Ambulatory Care; supplies costs pressured operating expenses. Tenet ended Q3 with $3.0 billion cash, ~$13.1 billion long-term debt, repurchased $93 million of stock in the quarter (≈$1.7 billion authorization remaining) and raised 2025 guidance (net operating revenues $21.15–21.35B; adjusted EBITDA $4.47–4.57B; adj EPS $15.93–16.26), providing a constructive near-term outlook despite some estimate downgrades and cost headwinds.

Analysis

Market structure: Tenet (THC) is a near-term winner — Q3 revenue +3.2% and adjusted EBITDA +12.4% to $1.1B with margin expansion of +170bps — driven by ambulatory buyouts (+11.9% revenue) and favorable payer mix. Smaller standalone hospitals and outpatient independents face loss of market share as Tenet scales facility buyouts and service-line expansion, pressuring local pricing dynamics. Rising supplies expense (+8.9% operating cost growth) is the key loser and caps margin upside if persistent.

Risk assessment: Major tail risks are reimbursement cuts, antitrust/transaction scrutiny from accelerated buyouts, prolonged supplies inflation, labor actions, and a refinancing shock against $13.1B long-term debt and ~$815–825M expected interest cost. Immediate (days) risk: momentum is weak (Momentum D) making pullbacks likely; short-term (weeks–months): guidance midpoints lifted but estimates trending down — catalysts could reverse quickly around next quarter; long-term (quarters–years): demographic + ambulatory secular tailwinds remain intact if integration executes.

Trade implications: Favor a controlled long THC exposure funded by reducing cyclicals; share buybacks ($1.7B authorization) and FCF midpoint ~$2.4B support EPS upside. Specific tactical plays: establish equity exposure or leveraged call spreads 1–3 month tenor ahead of the next earnings/guidance window, and consider a relative-value pair long THC / short UHS to capture mean reversion given UHS’s strong run. Use stops (12–15%) and size to limit downside.

Contrarian angles: Consensus underweights the durability of ambulatory growth and buyback optionality — upside if FCF realizes at the high end ($>2.4B) and buybacks accelerate. Conversely, consensus underestimates persistent supply-cost pressure; if supplies remain >200bps above trend marginally longer, margins could compress despite revenue growth. Historical parallel: post-recovery hospital rebounds can overshoot then mean-revert; position sizing must reflect that volatility.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Tenet (THC) within 2 weeks; target 20–30% upside over 3–6 months if adjusted EPS/guidance holds, trim half at +15% and stop-loss at -12–15%.
• Implement a pair trade: long THC 2% funded by short UHS 1% (dollar-neutral bias) to capture THC catch-up vs UHS after UHS’s 8% run; hold 3–6 months or until next quarterly results cycle.
• Use options for leveraged asymmetric exposure: buy a 3‑month THC call spread (buy 10% OTM, sell 30% OTM) sized to 25% of the equity position; alternatively sell a 3‑month 7% OTM put for ~max risk equal to 50% of notional if comfortable with assignment.
• Reallocate 3–5% from cyclical consumer names into medical-hospital sector exposure; monitor two triggers over 30–60 days — (1) FCF midpoint realization ≥$2.4B (accelerate buys) and (2) supplies cost increase >200bps y/y (reduce exposure).